# Five Prime Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/five-prime-therapeutics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Total disclosed funding: $30M
- Latest round: Series A (Apr 19, 2012)
- Investors on record: 11

## About

Based in California, US, and founded in 2001, Five Prime Therapeutics, Inc. develops immuno-oncology therapies intended for cancer patients. The company was founded by Lewis Williams and has offices located in San Francisco, US, Cambridge, US, Framingham, US, New York, US, and Seattle, US. In 2013, Five Prime Therapeutics, Inc. was publicly traded on the NASDAQ Global Market under the symbol FPRX., and in 2021, the company was acquired by Amgen Inc. Five Prime Therapeutics, Inc. develops therapeutics, under clinical trials, such as bemarituzumab - designed to block tumor growth causing cancer, FPT155 - stimulates anti-tumor immunity for solid tumors, FPA157 – helps enhance antibody-dependent cell-mediated cytotoxicity (ADCC) to eliminate cells causing cancer, and BMS-986258 (or TIM-3) – limits the duration and magnitude of cancer cells.

## Funding rounds

- Series A, Apr 19, 2012, $10M — Kleiner Perkins, Versant Ventures
- Series A, Aug 3, 2010, $7.5M — Domain Associates, Kleiner Perkins, Versant Ventures, Wellcome Trust, Johnson & Johnson, Inc., Mitsubishi UFJ Capital, Singapore Bio-Innovations, Fast Forward LLC
- Series B, Sep 23, 2003, $12M — Advanced Technology Ventures, Kleiner Perkins, Versant Ventures, Wellcome Trust, SG Growth Capital, TPG Biotech

## Investors

- Advanced Technology Ventures (https://capitalatlas.ai/funds/advanced-technology-ventures) — Series B
- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series B, Series A
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B, Series A
- Wellcome Trust — Series B, Series A
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series B
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series B
- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A
- Johnson & Johnson, Inc. — Series A
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A
- Singapore Bio-Innovations (https://capitalatlas.ai/funds/singapore-bio-innovations) — Series A
- Fast Forward LLC — Series A